Boston Globe

News & Analysis

boston globe and genzyme corp. and government - All News and Analysis

• Boston launches program to buy imported drugs.

  - 2004-07-22

  By Christopher Rowland, The Boston Globe Knight Ridder/Tribune Business News Jul. 22--Mayor Thomas M. Menino sent a strong message to Congress and the pharmaceutical industry yesterday by launching a pilot program to permit city employees and retirees to purchase prescription drugs ...

  Tags: Boston, Boston Globe, Canada, FDA, Genzyme Corp., Government

• The Boston Globe Biotechnology Briefs Column.

  - 2003-03-26

  By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News Mar. 26--Shares in Biopure Corp. fell 58 cents, or 19 percent, yesterday to $2.45 after the Cambridge company sold 5.55 million shares at a price of $2.42 each. The company, which is fast...

  Tags: Biotechnology, Boston Globe, Cambridge, Genzyme Corp., Government

• Career U-Turn Brings Ex-Counsel Back to Cambridge, Mass., Biotech Firm.

  - 2003-02-26

  By Jeffrey Krasner, The Boston Globe Knight Ridder/Tribune Business News Feb. 26----On Jan. 28, with considerable effort, Michael J. Astrue shaved and put on a tie. It was the first time he had attempted either task in 11 days. ...

  Tags: Biotechnology, board, Boston Globe, Cambridge, CAREER, director, FDA, Genzyme Corp., Government

• Shares Fall for Cambridge, Mass., Firm after Kidney Drug Fails to Perform.

  - 2002-11-28

  By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News Nov. 28--Shares of Transkaryotic Therapies Inc. tumbled 33 percent yesterday after the Cambridge firm said a study failed to show its drug, Replagal, improves kidney function in patients with a rare inherited ...

  Tags: Boston Globe, FDA, Genzyme Corp., Government, patient

• Investors Dump Shares of Cambridge, Mass.-Based Transkaryotic Therapies.

  - 2002-10-04

  By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News Oct. 4--Investors yesterday sold off nearly 23 million shares of Transkaryotic Therapies Inc., sending its stock down more than 60 percent, after the Cambridge firm said regulators had decided that a portion...

  Tags: Boston Globe, Cambridge, FDA, FINANCE, Genzyme Corp., Government, investor, stock

• Regulators Reject Data on Contested Pain-Reduction Drug As 'Uninterpretable'.

  - 2002-10-03

  By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News Oct. 3--Transkaryotic Therapies Inc. yesterday said regulators deemed its data on the reduction of pain, the main goal of the clinical studies supporting approval for its drug Replagal to treat the rare ...

  Tags: Boston Globe, FDA, Genzyme Corp., Government, regulator

• Regulators Request More Information from Cambridge, Mass.-Based Drug Maker.

  - 2001-10-23

  By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News Oct. 23--Genzyme Corp. said regulators won't approve its drug for Fabry disease until the Cambridge company provides more information about the drug's ability to treat the rare genetic disorder. The request from...

  Tags: Boston Globe, Cambridge, FDA, Genzyme Corp., Government, regulator

• Cambridge, Mass., Firms Fight to Provide First Drug for Genetic Disorder.

  - 2001-06-06

  The Boston Globe Knight Ridder/Tribune Business News Jun. 6--Transkaryotic Therapies Inc.'s drug Replagal markedly relieves pain and improves heart and kidney function in patients with Fabry disease, according to an article in today's Journal of the American Medical Association. The...

  Tags: Amgen Inc., Biotechnology, Boston Globe, Cambridge, Genzyme Corp., Government, HEALTHCARE, patient, survey

• Biotech Firm Sells Worcester, Mass.-Based Research Arm.

  - 2001-02-08

  By Ronald Rosenberg, The Boston Globe Knight Ridder/Tribune Business News Feb. 8--Looking to streamline its operations, Genzyme Transgenics Corp. yesterday said it plans to sell Primedica Corp., its preclinical research subsidiary, to Charles River Laboratories International for $51.9 million. Primedica,...

  Tags: biotechnology, Boston Globe, FINANCE, Genzyme Corp., Government, HEALTHCARE, Investment, IPO, Mortgages, River